

IN THE CLAIMS

Please amend the claims as follows:

1-24(Cancelled)

25. (Currently Amended) A method of promoting HIV-1- specific T-cell activity in a patient having an HIV-1 infection who has discontinued Highly Active Anti-retroviral Therapy ("HAART") [anti-HIV therapy] and experienced an increase in HIV-RNA plasma levels which comprises administering to such a patient an amount of pegylated interferon alpha for a time sufficient to lower HIV-RNA plasma level of the patient to a level below the patient's HIV-RNA plasma level prior to initiation of HAART [the anti-HIV-therapy].

26.(Cancelled)

27. (Original) The method of claim 25, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2a or pegylated interferon alfa-2b.

28. (Currently amended). The method of claim 25 which further comprises

- (a) re-initiating administering an effective amount of HAART [an anti-HIV therapy] for a time sufficient to lower HIV-RNA plasma levels below the detectable limit(50 HIV-RNA copies per mL of plasma);
- (b) discontinuing HAART and administering to such a patient an amount of pegylated interferon alpha for a time sufficient to lower HIV-RNA plasma level of the patient to a level below the patient's HIV-RNA plasma level prior to initiation of HAART .
- (c) re-initiating administering an effective amount of HAART [an anti-HIV therapy] for a time sufficient to lower HIV-RNA plasma levels below the detectable limit(50 HIV-RNA copies per mL of plasma).; and
- (d) discontinuing of HAART and administering to such a patient an amount of pegylated interferon alpha for a time sufficient to lower HIV-RNA plasma level of the patient to a level below the patient's HIV-RNA plasma level prior to initiation of HAART.

29-31(cancelled)

32. (Original) The method of claim 25, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2b and the effective amount is in the range of about 0.5 to about 3.0 micrograms per kilogram of pegylated interferon-alfa-2b once a week .

33. (Original) The method of claim 25, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2b and the effective amount is in the range of about 0.75 to about 1.5 micrograms per kilogram of pegylated interferon-alfa-2b administered once a week.

34. . (Original) The method of claim 25, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2b and the effective amount is in the range of about 1.5 micrograms per kilogram of pegylated interferon-alfa-2b administered once a week.

35. . (Original) The method of claim 25 wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2a and the effective amount of pegylated interferon alfa-2a administered is in the range of about 50 to about 500 micrograms per week.

36.(original) The method of claim 25, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2a and the effective amount of pegylated interferon alfa-2a administered is in the range of about 180 to about 250 micrograms per week.

37-40(cancelled)

41. (Currently amended) A method of promoting HIV-1-specific T-cell activity in a patient having an HIV-1 infection who has discontinued Highly Active Anti-retroviral Therapy ("HAART")and experienced an increase in HIV-RNA plasma levels which comprises administering to such a patient an effective amount of

interferon alpha in association with an effective amount HAART [an anti-HIV therapy] for a time sufficient to effect such promoting.

42. .(original) The method of claim 41 wherein the HIV-1-specific T-cells are cytotoxic T-lymphocytes.

43.(Cancelled)

44. .(original) The method of claim 43, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2a or pegylated interferon alfa-2b.

45. .(original) The method of claim 41, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2b and the effective amount is in the range of about 0.5 to about 3.0 micrograms per kilogram of pegylated interferon-alfa-2b once a week .

46. .(original) The method of claim 41, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2b and the effective amount is in the range of about 0.75 to about 1.5 micrograms per kilogram of pegylated interferon-alfa-2b administered once a week.

47. .(original) The method of claim 41, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2b and the effective amount is in the range of about 1.5 micrograms per kilogram of pegylated interferon-alfa-2b administered once a week.

48. .(original) The method of claim 41, wherein the pegylated interferon-alfa administered is a pegylated interferon alfa-2a and the effective amount of pegylated interferon alfa-2a administered is in the range of about 50 to about 500 micrograms per week.

49. (Original) The method of claim 41, wherein the pegylated interferon-alfa administered is pegylated interferon alfa-2a and the effective amount of pegylated interferon-alfa-2b administered is in the range of about 180 to about 250 micrograms per week.